tiprankstipranks
Trending News
More News >
Virbac SA (FR:VIRP)
:VIRP

Virbac SA (VIRP) AI Stock Analysis

Compare
8 Followers

Top Page

FR

Virbac SA

(LSE:VIRP)

Rating:75Outperform
Price Target:
€359.00
▲(10.29%Upside)
Virbac SA's strong financial performance is a key driver of its overall score, reflecting solid profitability and growth with minimal leverage. Technical analysis supports the stock's positive momentum, while its valuation remains reasonable. The lack of earnings call data and corporate events did not impact the score.
Positive Factors
Regional Growth
Europe and Latin America are experiencing robust growth rates of around 8%, contributing positively to Virbac's overall performance.
Sales Performance
Virbac's first-quarter sales figures met expectations with organic growth of 4.9%.
Negative Factors
Earnings Growth
There is a likelihood of a slowdown in earnings growth in the first half of the year due to an unfavorable base effect.
Regional Decline
Australia is experiencing a significant decline with a 15% decrease, negatively impacting Virbac's sales in the Pacifique region.

Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)

Virbac SA Business Overview & Revenue Model

Company DescriptionVirbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
How the Company Makes MoneyVirbac SA generates revenue through the sale of its diverse portfolio of animal health products, catering to both companion animals and livestock. Key revenue streams include veterinary pharmaceuticals, vaccines, and nutritional products. The company focuses on developing innovative solutions to meet the evolving needs of the animal health industry, leveraging research and development to create advanced products. Additionally, Virbac engages in strategic partnerships and collaborations with veterinary clinics, distributors, and research institutions, which help in expanding market reach and enhancing product offerings. These partnerships, along with a robust distribution network, play a significant role in driving the company's earnings.

Virbac SA Financial Statement Overview

Summary
Virbac SA demonstrates a strong financial profile with consistent revenue growth, robust profitability margins, and minimal leverage. The company effectively manages costs and utilizes shareholder equity efficiently, while maintaining solid cash flow generation.
Income Statement
85
Very Positive
Virbac SA demonstrates a strong income statement with consistent revenue growth over the years. Gross Profit Margin in 2024 is approximately 67.4%, reflecting efficient cost management. Net Profit Margin stands at about 10.4%, indicating a solid profitability level. EBIT Margin of 15.5% and EBITDA Margin of 20.4% showcase robust operational efficiency. Revenue grew by approximately 12.1% from 2023 to 2024, indicating a healthy upward trajectory. Overall, the company shows strong profitability and growth, with a continuous positive trend.
Balance Sheet
80
Positive
The balance sheet of Virbac SA is stable with a low Debt-to-Equity Ratio of 0.04, indicating minimal leverage and financial risk. Return on Equity (ROE) is approximately 13.9%, showcasing effective utilization of shareholder equity to generate profits. The Equity Ratio of 56.4% suggests a solid capital structure with a significant portion of assets financed by equity. These metrics indicate financial stability and a well-managed balance sheet with minimal debt risk.
Cash Flow
78
Positive
Virbac SA's cash flow statement shows solid cash generation capabilities with a Free Cash Flow Growth Rate of approximately 128.5% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is about 1.4, indicating good cash conversion. Free Cash Flow to Net Income Ratio stands at 0.93, reflecting efficient management of capital expenses. The company exhibits strong cash flow management, though a higher free cash flow conversion ratio would further enhance its cash flow position.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.40B1.25B1.22B1.06B934.20M
Gross Profit
937.60M422.67M427.27M378.38M290.41M
EBIT
217.07M184.88M173.33M160.10M112.04M
EBITDA
284.85M230.65M215.55M199.46M231.67M
Net Income Common Stockholders
145.29M121.30M121.97M113.16M136.04M
Balance SheetCash, Cash Equivalents and Short-Term Investments
149.63M175.91M177.38M172.79M181.89M
Total Assets
1.85B1.46B1.36B1.22B1.11B
Total Debt
307.01M120.11M91.49M95.37M116.22M
Net Debt
157.38M-55.80M-85.89M-77.41M-65.67M
Total Liabilities
805.12M545.81M521.17M498.84M454.28M
Stockholders Equity
1.04B900.30M839.33M724.93M620.97M
Cash FlowFree Cash Flow
134.97M59.06M45.41M79.13M81.23M
Operating Cash Flow
204.22M118.64M98.98M126.29M110.22M
Investing Cash Flow
-428.69M-121.87M-54.83M-106.22M339.52M
Financing Cash Flow
138.59M-2.56M-34.76M-33.07M-341.19M

Virbac SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price325.50
Price Trends
50DMA
308.12
Positive
100DMA
309.05
Positive
200DMA
327.20
Negative
Market Momentum
MACD
6.15
Negative
RSI
58.79
Neutral
STOCH
52.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 325.5 is above the 20-day moving average (MA) of 318.93, above the 50-day MA of 308.12, and below the 200-day MA of 327.20, indicating a neutral trend. The MACD of 6.15 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 52.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.

Virbac SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
FRSAN
76
Outperform
$107.82B19.907.34%4.12%-4.62%2.88%
75
Outperform
€2.73B18.7614.95%0.40%12.07%20.48%
73
Outperform
€858.58M14.5910.64%1.17%1.88%5.79%
FRIPN
68
Neutral
€8.64B25.008.89%1.15%8.73%-46.34%
FRBOI
62
Neutral
€402.93M35.232.94%5.89%-1.15%-68.36%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
37
Underperform
€533.73M
-1.66%-6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:VIRP
Virbac SA
326.00
-26.17
-7.43%
FR:VETO
VETOQUINOL
74.60
-26.79
-26.42%
FR:IPN
Ipsen
104.00
-15.29
-12.81%
FR:SAN
Sanofi
87.47
1.37
1.59%
FR:BOI
Boiron SA
23.00
-10.64
-31.64%
FR:MEDCL
MedinCell SA
16.00
1.24
8.40%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.